Pediatric myelin oligodendrocyte glycoprotein antibody associated disease-Asymmetric papilledema and elevated ICP are two of the chameleons: A case report

Medicine (Baltimore). 2023 Feb 22;102(8):e32986. doi: 10.1097/MD.0000000000032986.

Abstract

Background: Myelin oligodendrocyte glycoprotein antibody (MOGA) associated diseases are inflammatory immune-mediated demyelinating disorders with relapse potential involving the central nervous system. Multiple unusual clinical manifestations of those disorders were reported, making treatment decisions difficult.

Case presentation: A healthy 12-year-old obese boy presented with headache and bilateral asymmetric papilledema. The patient had a negative medical history. His neurological and general examinations were unremarkable, his initial magnetic resonance imaging showed elevated intracranial pressure (ICP) only. A lumbar puncture revealed increased opening pressure and pleocytosis. The MOGA titer was 1:320. He needed acetazolamide and steroid therapy. After 2 months of medication, weight loss, exercise, the patient symptoms significantly improved, papilledema resolved, and visual function improved.

Conclusion: MOGA-associated disorders have a variety of clinical features, so a high index of suspicion is required for their diagnosis. Papilledema and an elevated ICP are 2 of the chameleons of MOGA-associated disorders. MOGA test may be useful in patients with elevated ICP and inflammatory cerebrospinal fluid profiles. An investigation of the possible association between those disorders and high ICP is warranted.

Publication types

  • Case Reports

MeSH terms

  • Acetazolamide / therapeutic use
  • Headache / etiology
  • Humans
  • Intracranial Hypertension* / drug therapy
  • Male
  • Myelin-Oligodendrocyte Glycoprotein
  • Papilledema* / etiology

Substances

  • Myelin-Oligodendrocyte Glycoprotein
  • Acetazolamide